ENVB Stock Analysis: Buy, Sell, or Hold?
ENVB - Enveric Biosciences, Inc. Common Stock
$1.41
-0.02 (-1.40%)
âŧ
5d:
-4.73%
30d:
+9.3%
90d:
-36.2%
WAIT
LOW Confidence
Analysis Updated: Aug 24, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When ENVB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ENVB is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ENVB is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: ENVB is currently trading at $1.41, which is considered fair relative to its 30-day fair value range of $1.32 to $1.57.
Technical Outlook: Technically, ENVB is in a downtrend. Immediate support is located at $1.25, while resistance sits at $1.62.
Market Sentiment: ENVB scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.00 (+609.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ENVB is in a downtrend. Immediate support is located at $1.25, while resistance sits at $1.62.
Market Sentiment: ENVB scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.00 (+609.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.32 -
$1.57
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (30/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 609.2% below Wall St target ($10.00)
- WARNING: Composite score 48/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.32 -
$1.57
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.25
Resistance Level
$1.62
Current Trend
Downtrend
Technical data as of
Aug 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
23.09
Wall Street Target
$10.00
(+609.2%)
Revenue Growth (YoY)
-7.3%
Share & Embed Analysis
Last updated: August 25, 2026 5:13 AM ET
Data refreshes hourly during market hours. Next update: 6:13 AM
Data refreshes hourly during market hours. Next update: 6:13 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ENVB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 65 BUY |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 38 SELL |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 39 SELL |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 34 SELL |
|
CRNX
Crinetics PharmaceuticalâĻ |
STRONG BUY
17 analysts |
$86 | 41 HOLD |
